


## Aminoxy-PEG5-azide

|                    |  |
|--------------------|--|
| Cat. No.:          | HY-130507  |
| CAS No.:           | 1919045-02-5   |
| Molecular Formula: | C <sub>12</sub> H <sub>26</sub> N <sub>4</sub> O <sub>6</sub>  |
| Molecular Weight:  | 322.36   |
| Target:            | PROTAC Linkers   |
| Pathway:           | PROTAC   |
| Storage:           | 4°C, sealed storage, away from moisture<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



### SOLVENT & SOLUBILITY

|   |   |                          |           |            |            |
|---|---|--------------------------|-----------|------------|------------|
| In Vitro  | DMSO : 100 mg/mL (310.21 mM; Need ultrasonic) |                          |           |            |            |
|   |   | Solvent<br>Concentration | Mass      |            |            |
|   | Preparing<br>Stock Solutions                  |                          | 1 mg      | 5 mg       | 10 mg      |
|   |   | 1 mM                     | 3.1021 mL | 15.5106 mL | 31.0212 mL |
|   |   | 5 mM                     | 0.6204 mL | 3.1021 mL  | 6.2042 mL  |
|   | 10 mM   | 0.3102 mL                | 1.5511 mL | 3.1021 mL  |            |
| Please refer to the solubility information to select the appropriate solvent. |   |                          |           |            |            |

### BIOLOGICAL ACTIVITY

|                           |  |
|---------------------------|--|
| Description               | Aminoxy-PEG5-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs <sup>[1]</sup> . Aminoxy-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups. |
| IC <sub>50</sub> & Target | PEGs   |
| In Vitro                  | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.   |

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA